Concept to IND
Tailored to Your Needs

Where discovery meets IND, one partner for preclinical excellence
Who we are

Medicilon is committed to support our partners every step along their unique drug discovery journey

From precision chemical synthesis to preclinical advancements – ADME/DMPK, pharmacology, and safety – we deliver holistic solutions tailored to your innovations.

Our history

Transforming global drug discovery by empowering pharmaceutical innovators

Years of Experience

20+

IND-Approved Projects

690+

DMPK/ADME Studies

>10,000 compounds/ year

Our Services

Unified expertise, building a path to your success

Combining advanced capabilities in biology, chemistry, and preclinical research, we deliver tailored services that take you seamlessly from drug discovery to IND.

Drug Discovery

Driving drug discovery through unrivaled chemical synthesis and integrated biologics.

CMC Development

From process development to GMP manufacturing – for a seamless path to IND.

Preclinical Research

Where ADME/DMPK and Toxicology intersect to de-risk programs and accelerate clinical progress. Non-GLP and GLP studies ensure flexibility for early research and compliance for regulatory submission.

ADME/DMPK
Optimize drug candidates with comprehensive DMPK/ADME insights.
Pharmacology
Uncover drug efficacy and mechanisms with expert pharmacology solutions.
Safety Assessment
Ensure therapeutic safety with comprehensive and reliable toxicology services.
Our promises

Expertise, innovation, and partnership

Innovation First

Harnessing cutting-edge technology to solve complex challenges.

Unwavering Dedication

Driving success through respect, collaboration, and passion.

Client-Centric Excellence

Setting the gold standard in quality, speed, compliance, and IP protection.

Mutual Success

Building lasting partnerships rooted in trust and shared goals

Tailored preclinical solutions to propel your innovations from discovery to clinical milestones

Search Medicilon

Preclinical CRO

Medicilon Congratulates : MindRank AI-Developed Oral GLP-1 MDR-001 Secures Up to RMB 1.75 Billion Exclusive Commercialization Deal with Sunshine Mandi

Preclinical CRO

A Note of Appreciation, A Mark of Recognition | Medicilon Supports Partner Tasly in Obtaining Clinical Trial Approval for TSL2402 Tablets

Preclinical CRO

BIOJAPAN 2026

Contact Medicilon

Name(Required)
Address(Required)